

NSC23925

Catalog No: **tcsc0016032**



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg



Specifications

CAS No:

858474-14-3

Formula:

$C_{22}H_{26}Cl_2N_2O_2$

Pathway:

Membrane Transporter/Ion Channel

Target:

P-glycoprotein

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

421.36

Product Description


NSC23925 is a novel, selective and effective **P-glycoprotein (Pgp)** inhibitor.

IC50 & Target: P-glycoprotein^[1]

In Vitro:

NSC23925 is a novel, selective and effective P-glycoprotein (Pgp) inhibitor. SKOV-3 cells with long-term exposure of 1 μM NSC23925 show stable growth in culture medium. NSC23925 specifically inhibits Pgp overexpression to prevent the emergence of paclitaxel resistance during paclitaxel treatment^[1]. NSC23925 reverses chemoresistance in a wide variety of tumor types where Multidrug resistance 1 (MDR1) is highly expressed. Maximal reversal of MDR is typically seen in NSC23925 doses between 0.5 and 1 μM . The IC_{50} for NSC23925 is 8 μM in SKOV-3/SKOV-3_{TR} and 25 μM in OVCAR8/OVCAR8_{TR} cell lines, whereas the mean concentration of NSC23925 required for maximal reversal of resistance in SKOV-3_{TR} or OVCAR8_{TR} to cytotoxic drugs is 0.5 μM to 1 μM ^[2].

In Vivo: Both saline alone and NSC23925 alone treated tumors grow progressively. The usage of NSC23925 in paclitaxel chemotherapy significantly prolongs anticancer efficacy of paclitaxel^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!